Wells Fargo
ADCT icon

Wells Fargo’s ADC Therapeutics ADCT Stock Holding History

Wells Fargo’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$985K Sell
262,783
-57,265
-18% -$226K ﹤0.01% 3748
2025
Q4 		$1.13M Buy
320,048
+250,547
+360% +$1.02M ﹤0.01% 3871
2025
Q3 		$278K Buy
69,501
+7,060
+11% +$22.3K ﹤0.01% 4728
2025
Q2 		$167K Sell
62,441
-5,336
-8% -$11.2K ﹤0.01% 4871
2025
Q1 		$95.6K Buy
67,777
+25,945
+62% +$44.1K ﹤0.01% 5118
2024
Q4 		$83.2K Buy
41,832
+11,834
+39% +$31K ﹤0.01% 5296
2024
Q3 		$94.5K Buy
29,998
+4,294
+17% +$13.5K ﹤0.01% 5052
2024
Q2 		$81.2K Buy
+25,704
New +$102K ﹤0.01% 5065
2022
Q4 		– Sell
-200
Closed -$1K – 7433
2022
Q3 		$1K Hold
200
– – ﹤0.01% 6252
2022
Q2 		$2K Hold
200
– – ﹤0.01% 6281
2022
Q1 		$3K Hold
200
– – ﹤0.01% 6563
2021
Q4 		$4K Sell
200
-333
-62% -$8.03K ﹤0.01% 6732
2021
Q3 		$14K Sell
533
-267
-33% -$6.84K ﹤0.01% 6082
2021
Q2 		$19K Sell
800
-1,400
-64% -$32.5K ﹤0.01% 5915
2021
Q1 		$54K Buy
+2,200
New +$63.7K ﹤0.01% 5773

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Wells Fargo's ADCT Position: Q1 2026 in Review

Wells Fargo reduced its ADC Therapeutics (ADCT) stake by 18% in Q1 2026, selling an estimated $226K and leaving 262,783 shares worth $985K. The position accounts for ﹤0.01% of the portfolio, ranked #3748.

Wells Fargo first reported a position in ADCT in Q1 2021 and has held it in 15 quarters since. The position peaked at $1.13M in Q4 2025. 118 funds tracked by Wall St. Rank hold ADCT as of Q1 2026.

  • Wells Fargo held 262,783 shares of ADC Therapeutics worth $985K as of Q1 2026.
  • Wells Fargo sold 57,265 ADC Therapeutics shares in Q1 2026, an estimated $226K.
  • ADC Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3748 holding.
  • Wells Fargo first reported a position in ADC Therapeutics in Q1 2021 and has held it in 15 quarters since.
  • Wells Fargo's ADC Therapeutics position peaked at $1.13M in Q4 2025.
  • 118 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.